- Home
- AEON vs INAB Comparison
AEON vs INAB Comparison
Compare AEON & INAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEON | INAB |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 25.2M | 22.9M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | AEON | INAB |
|---|---|---|
| Price | $1.04 | $1.96 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 2 |
| Target Price | $7.20 | ★ $108.00 |
| AVG Volume (30 Days) | ★ 236.3K | 71.3K |
| Earning Date | 03-23-2026 | 03-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $1.17 |
| 52 Week High | $10.01 | $12.53 |
Technical Indicators
Market Signals| Indicator | AEON | INAB |
|---|---|---|
| Relative Strength Index (RSI) | 42.91 | 40.68 |
| Support Level | $1.01 | $1.85 |
| Resistance Level | $1.13 | $2.07 |
| Average True Range (ATR) | 0.08 | 0.15 |
| MACD | -0.02 | -0.04 |
| Stochastic Oscillator | 7.69 | 1.54 |
Price Performance
Historical ComparisonAbout AEON AEON Biopharma Inc.
AEON Biopharma Inc is a clinical stage biopharmaceutical company focused on developing of its proprietary botulinum toxin complex ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, with an initial focus on the neurosciences market.
About INAB IN8bio Inc.
IN8bio Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of gamma-delta T cell product candidates for solid and liquid tumors, by employing allogeneic, autologous, and genetically modified gamma-delta T cells. Its product candidates include INB-400, for the treatment of newly diagnosed glioblastoma, or GBM, INB-100 for the treatment of patients with high-risk leukemias undergoing hematopoietic stem cell transplantation, and other product candidates such as INB-200, INB-300, and INB-500.